Bulluck Heerajnarain, Maestrini Viviana, Rosmini Stefania, Abdel-Gadir Amna, Treibel Thomas A, Castelletti Silvia, Bucciarelli-Ducci Chiara, Manisty Charlotte, Moon James C
Heart Hospital Imaging Centre, Barts Heart Centre; Hatter Cardiovascular Institute, University College London.
Circ J. 2015;79(3):487-94. doi: 10.1253/circj.CJ-15-0054. Epub 2015 Feb 6.
Cardiovascular magnetic resonance is a well-established tool for the quantification of focal fibrosis. With the introduction of T1 mapping, diffuse myocardial processes can be detected and quantified. In particular, infiltration and storage disorders with large disease-related changes, and diffuse fibrosis where measurement is harder but the potential impact larger. This has added a new dimension to the understanding and assessment of various myocardial diseases. T1 mapping promises to detect early disease, quantify disease severity and provide prognostic insights into certain conditions. It also has the potential to be a robust surrogate marker in drug development trials to monitor therapeutic response and be a prognostic marker in certain diseases. T1 mapping is an evolving field and numerous factors currently preclude its standardization. In this review, we describe the current status of T1 mapping and its potential promises and pitfalls.
心血管磁共振成像（CMR）是一种成熟的用于定量局灶性纤维化的工具。随着T1 mapping技术的引入，可以检测和量化弥漫性心肌病变。特别是对于伴有与疾病相关的重大变化的浸润性和贮积性疾病，以及测量难度较大但潜在影响更大的弥漫性纤维化。这为各种心肌疾病的理解和评估增添了新的维度。T1 mapping有望检测早期疾病、量化疾病严重程度并为某些病症提供预后见解。它还有可能成为药物研发试验中监测治疗反应的有力替代标志物以及某些疾病的预后标志物。T1 mapping是一个不断发展的领域，目前有许多因素阻碍其标准化。在这篇综述中，我们描述了T1 mapping的现状及其潜在的前景与陷阱。
